Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poly ICLC - Oncovir

Drug Profile

Poly ICLC - Oncovir

Alternative Names: Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acid

Latest Information Update: 14 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical University of South Carolina; Oncovir
  • Developer Abramson Cancer Center of the University of Pennsylvania; Augusta University; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; immatics biotechnologies GmbH; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); New York University School of Medicine; Oncovir; Quest PharmaTech; Roswell Park Cancer Institute; University Hospitals of Geneva; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Natural killer cell stimulants; Natural killer T cell stimulants; Proto oncogene protein c rel modulators; Proto oncogene protein c-ret modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer; Flavivirus infections; Orthopoxvirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Ovarian cancer; Solid tumours
  • Phase I/II B-cell lymphoma; Breast cancer; Colorectal cancer; Glioblastoma; Head and neck cancer; HIV infections; Non-Hodgkin's lymphoma
  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Glioma; Myelodysplastic syndromes; Prostate cancer
  • No development reported Anaplastic astrocytoma; Cytomegalovirus infections; Influenza virus infections; Pancreatic cancer; Smallpox

Most Recent Events

  • 25 Sep 2019 Washington University School of Medicine plans a phase I trial for Pancreatic cancer in the US (SC) (NCT03956056)
  • 21 Jun 2019 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory, Second-line therapy or greater) in USA (IM) (NCT03835533)
  • 31 May 2019 Immunogenicity data from a phase I/II trial in Melanoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top